Mineralys Therapeutics (NASDAQ: MLYS) insider transactions
In the twelve months to 10 November 2026, executives and directors of Mineralys Therapeutics reported 80 open-market sales of 2,318,269 shares ($88.0m) and 2 open-market purchases of 369,000 shares ($8.8m), by 9 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 19 October 2026 | Peterson Kristine | Director | Grant or award | +12,400 | — | 12,400 | Form 4 |
| 19 October 2026 | Coats Lonnel | Director | Grant or award | +12,400 | — | 12,400 | Form 4 |
| 30 September 2026 | Congleton Jon | Chief Executive Officer | Open-market sale, 10b5-1 plan | −75,000 | $25.46 | 528,621 | Form 4 |
| 22 September 2026 | Slingsby Brian Taylor | Director | Open-market sale | −104,320 | $28.81 | 7,805,718 | Form 4 |
| 21 September 2026 | Warren Eric | Chief Commercial Officer | Option exercise, 10b5-1 plan | +7,438 | $13.24 | 45,838 | Form 4 |
| 21 September 2026 | Warren Eric | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −7,438 | $28.12 | 38,400 | Form 4 |
| 15 September 2026 | Karydas Daphne | Director | Option exercise, 10b5-1 plan | +3,000 | $12.02 | 9,200 | Form 4 |
| 15 September 2026 | Karydas Daphne | Director | Open-market sale, 10b5-1 plan | −3,000 | $28.58 | 6,200 | Form 4 |
| 21 August 2026 | Warren Eric | Chief Commercial Officer | Option exercise, 10b5-1 plan | +7,437 | $13.24 | 45,837 | Form 4 |
| 21 August 2026 | Warren Eric | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −7,437 | $25.98 | 38,400 | Form 4 |
| 10 August 2026 | Rodman David Malcom | Chief Medical Officer | Option exercise, 10b5-1 plan | +2,170 | $16.00 | 53,554 | Form 4 |
| 10 August 2026 | Rodman David Malcom | Chief Medical Officer | Open-market sale, 10b5-1 plan | −2,170 | $27.09 | 51,384 | Form 4 |
| 10 August 2026 | Ferguson James J. III | Chief Medical Officer | Grant or award | +102,400 | — | 102,400 | Form 4 |
| 21 July 2026 | Warren Eric | Chief Commercial Officer | Option exercise, 10b5-1 plan | +7,438 | $13.24 | 45,838 | Form 4 |
| 21 July 2026 | Warren Eric | Chief Commercial Officer | Open-market sale, 10b5-1 plan | −7,438 | $26.87 | 38,400 | Form 4 |
| 17 July 2026 | Rodman David Malcom | Chief Medical Officer | Option exercise, 10b5-1 plan | +416 | $15.44 | 51,800 | Form 4 |
| 17 July 2026 | Rodman David Malcom | Chief Medical Officer | Open-market sale, 10b5-1 plan | −416 | $26.53 | 51,384 | Form 4 |
| 15 July 2026 | Rodman David Malcom | Chief Medical Officer | Open-market sale, 10b5-1 plan | −6,349 | $26.61 | 51,384 | Form 4 |
| 13 July 2026 | Rodman David Malcom | Chief Medical Officer | Option exercise, 10b5-1 plan | +3,542 | $10.20 | 61,275 | Form 4 |
| 13 July 2026 | Rodman David Malcom | Chief Medical Officer | Option exercise, 10b5-1 plan | +4,167 | $14.25 | 65,442 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Mineralys Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.